Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and Biotransformation Study of [14C] Donafenib in Healthy Volunteers
NCT04816123Phase 1Completed
- Sponsor
- Zelgen
- Start
- Oct 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Zelgen. Primary endpoints: Quantitive analysis of whole radioactivity of excrement, Identification of the main metabolite and biotransformation pathway and 1 more. Started Oct 2018; status: completed.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04816123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04816123.